LRRK2 levels in immune cells are increased in Parkinson's disease

npj Parkinson's Disease

Volumn 3, Issue 1, 2017, Pages

  Cook, D A ^a   Kannarkat, G T ^a   Cintron, A F ^a   Butkovich, Laura M ^a   Fraser, Kyle B ^b   Chang, J ^a   Grigoryan, N ^a   Factor, S A ^a   West, Andrew B ^b   Boss, J M ^a   Tansey, M G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; LRRK2 GENE; MONOCYTE; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 85084783827     PISSN: None     EISSN: 23738057     Source Type: Journal    
DOI: 10.1038/s41531-017-0010-8     Document Type: Article

References (53)

1. Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
2. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
3. Thaler, A., Ash, E., Gan-Or, Z., Orr-Urtreger, A. & Giladi, N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J. Neural. Transm. 116, 1473-1482 (2009).
4. Aasly, J. O. et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann. Neurol. 57, 762-765 (2005).
5. Haugarvoll, K. et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70, 1456-1460 (2008).
6. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P. & Gallo, K. A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293 (2009).
7. Funayama, M. et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11. 2-q13. 1. Ann. Neurol. 51, 296-301 (2002).
8. Guo, L. et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658-3670 (2007).
9. Gilsbach, B. K. et al. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc. Natl Acad. Sci. USA 109, 10322-10327 (2007).
10. Manzoni, C. et al. mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1. Sci. Rep. 6, 35106 (2016).
11. Ferrazza, R. et al. LRRK2 deficiency impacts ceramide metabolism in brain. Biochem. Biophys. Res. Commun. 478, 1141-1146 (2016).
12. Plowey, E. D., Cherra, S. J., Liu, Y. J. & Chu, C. T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048-1056 (2008).
13. Schapansky, J., Nardozzi, J. D., Felizia, F. & LaVoie, M. J. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum. Genet. 23, 4201-4214 (2014).
14. Ramonet, D. et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 6, e18568 (2011).
15. Berwick, D. C. & Harvey, K. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum. Genet. 21, 4966-4979 (2012).
16. Liu, Z. et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 12, 1063-1070 (2011).
17. Hongge, L., Kexin, G., Xiaojie, M., Nian, X. & Jinsha, H. The role of LRRK2 in the regulation of monocyte adhesion to endothelial cells. J. Mol. Neurosci. 55, 233-239 (2015).
18. Brice, A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128(Pt 12), 2760-2762 (2005).
19. Rudenko, I. N. & Cookson, M. R. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics 11, 738-750 (2014).
20. Rideout, H. J. & Stefanis, L. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease. Neurochem. Res. 39, 576-592 (2014).
21. Greggio, E. & Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 1, AN20090007 (2009).
22. Hakimi, M. et al. Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural. Transm. 118, 795-808 (2011).
23. Gardet, A. et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185, 5577-5585 (2010).
24. Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
25. Zhang, F. R. et al. Genomewide association study of leprosy. N. Eng. J. Med. 361, 2609-2618 (2009).
26. Meylan, E. & Tschopp, J. The RIP kinases: crucial integrators of cellular stress. TIBS 30, 151-159 (2005).
27. Zhang, D., Lin, J. & Han, J. Receptor-interacting protein (RIP) kinase family. Cell. Mol. Immunol. 7, 243-249 (2010).
28. Thevenet, J., Pescini-Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C. & Sagot, Y. J. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE 6, e21519 (2011).
29. Kuss, M., Adamopoulou, E. & Kahle, P. J. Interferon-gamma induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages. J. Neurochem. 129, 980-987 (2014).
30. Moehle, M. S. et al. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602-1611 (2012).
31. Perera, G., Ranola, M., Rowe, D. B., Halliday, G. M. & Dzamko, N. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Sci. Rep. 6, 31391 (2016).
32. Russo, I., Bubacco, L. & Greggio, E. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease J. Neuroinflammation 11, 52 (2014).
33. Pradhan, S. & Andreasson, K. Commentary: progressive inflammation as a contributing factor to early development of Parkinson's disease. Exp. Neurol. 241, 148-155 (2013).
34. Neumann, H., Kotter, M. R. & Franklin, R. J. M. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132, 288-295 (2009).
35. McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurol. 38, 1285-1291 (1988).
36. Whitton, P. S. Inflammation as a causative factor in the aetiology of Parkinson's disease. British. J. Pharmacol. 150, 963-976 (2007).
37. Saunders, J. A. et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J. Neuroimmune Pharmacol 7, 927-938 (2012).
38. Gillardon, F., Schmid, R. & Draheim, H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neurosci. 208, 41-48 (2012).
39. Waldburger, J. M. et al. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol. Rev. 178, 148-165 (2000).
40. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. & Amigorena, S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667 (2002).
41. Chardin, P. & McCormick, F. Brefeldin A: the advantage of being uncompetitive. Cell 97, 153-155 (1999).
42. Ziegler-Heitbrock, L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 81, 584-592 (2007).
43. Grozdanov, V. et al. Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. Acta Neuropathol. 128, 651-663 (2014).
44. Deng, X. et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205 (2011).
45. Kannarkat, G. T. et al. Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson's disease: an observational and case-control study. NPJ Parkinsons Dis. 1, 15002 (2015).
46. Gibson, H. M. et al. Induction of the CTLA-4 Gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J. Immunol. 179, 3831-3840 (2007).
47. Mount, M. P. et al. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 27, 3328-3337 (2007).
48. Mogi, M. et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150 (1994).
49. Blum-Degen, D. et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20 (1995).
50. Chen, H. et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 74, 878-884 (2010).
51. Gagne, J. J. & Power, M. C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995-1002 (2010).
52. Hernán, M. A., Takkouche, B., Caamaño-Isorna, F. & Gestal-Otero, J. J. A metaanalysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52, 276-284 (2002).
53. Chen, H. et al. Nonsteroidal anti-inflammatory drugs and the risk of parkinson disease. Arch. Neurol. 60, 1059-1064 (2003).